**Wednesday, February 23, 2022**

10:00 **Welcome & Introductions**  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:20 **Tickborne Encephalitis (TBE) Vaccine**  
**Introduction**  
Dr. Katherine Poehling (ACIP WG Chair)  
**Review of considerations for use of TBE vaccine in travelers and laboratorians**  
Dr. Susan Hills (CDC/NCEZID)  
**Proposed recommendations**  
Dr. Susan Hills (CDC/NCEZID)

11:15 **Cholera Vaccine**  
**Introduction**  
Dr. Pablo Sanchez (ACIP, WG Chair)  
**Clinical considerations for use of cholera vaccine in children and adolescents aged 2–17 years**  
Dr. Jennifer Collins (CDC/NCEZID)  
**Proposed recommendations**  
Dr. Jennifer Collins (CDC/NCEZID)

11:50 **Break**

12:10 **Influenza Vaccine**  
**Introduction**  
Dr. Keipp Talbott (ACIP, WG Chair)  
**Influenza activity update**  
Dr. Lisa Grohskopf (CDC/NCIRD)  
**Recommending enhanced seasonal influenza vaccines in adults age 65 and older--potential impacts on influenza burden**  
Dr. Sinead Morris (CDC/NCIRD)  
**Influenza vaccines for older adults**  
Dr. Lisa Grohskopf (CDC/NCIRD)

1:10 **Hepatitis Vaccine**  
**Introduction**  
Dr. Kevin Ault (ACIP, WG Chair)  
**PREHEVBRI0 for adult HepB vaccination: EtR and GRADE**  
Dr. Mark Weng (CDC/NCHHSTP)

1:40 **Break**

1:55 **MMR Vaccine Workgroup**  
**Introduction**  
Ms. Lynn Bahta (ACIP, WG Chair)  
**MMR safety and immunogenicity**  
Dr. Remon Abu-Elyazeed (GSK)

2:25 **Public Comment**

2:45 **VOTE**  
**TBE Vaccine**  
Dr. Susan Hills (CDC/NCEZID)  
**Cholera Vaccine**  
Dr. Jennifer Collins (CDC/NCEZID)

4:00 **Adjourn**

---

**Thursday, February 24, 2022**

10:00 **Welcome & Introductions**  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:10 **Agency Updates**  
CDC, CMS, FDA, HRSA, HIS, OIDP, NIH

10:25 **Pneumococcal Vaccines**  
**Introduction**  
Dr. Katherine Poehling (ACIP, WG Chair)  
**Epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US children**  
Mr. Ryan Gierke (CDC/NCIRD)  
**PCV15 Phase 2/3 study results in children**  
Dr. Natalie Banniettis (Merck)  
**GRADE and EtR for PCV15 use in U.S. children**  
Ms. Jennifer Farrar (CDC/NCIRD)  
**Summary and next steps**  
Dr. Miwako Kobayashi (CDC/NCIRD)

12:15 **Adjourn**
<table>
<thead>
<tr>
<th>Acronyms</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>EtR</td>
<td>Evidence to Recommendations Framework</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>NCHHSTP</td>
<td>National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]</td>
</tr>
<tr>
<td>NCIRD</td>
<td>National Center for Immunization &amp; Respiratory Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NCEZID</td>
<td>National Center for Emerging and Zoonotic Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NIAID</td>
<td>National Institute of Allergy and Infectious Diseases</td>
</tr>
<tr>
<td>OIDP</td>
<td>Office of Infectious Disease and HIV/AIDS Policy</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe Acute Respiratory Syndrome Coronavirus 2</td>
</tr>
<tr>
<td>WG</td>
<td>Work Group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>VE</td>
<td>Vaccine Effectiveness</td>
</tr>
</tbody>
</table>